4-acetoxy-3-tert-butylphenol | 216314-06-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 4-acetoxy-3-tert-butylphenol
• 英文别名: t-butyl-4-hydroxy-phenyl acetate；4-acetoxy-3-t-butylphenol；tert-butyl-4-hydroxy phenyl acetate；(2-tert-butyl-4-hydroxyphenyl) acetate
• CAS: 216314-06-6
• 化学式: C₁₂H₁₆O₃
• 分子量: 208.257
• InChiKey: DXKFWNAKGVBFHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-acetoxy-3-tert-butylphenol 在 乌洛托品 作用下， 以 正己烷 、 乙酸乙酯 、 三氟乙酸 为溶剂， 以52%的产率得到5-acetoxy-4-t-butyl-2-hydroxybenzaldehyde
  参考文献：
  名称：

  2,3-dihydrobenzofuran derivatives

  摘要：

  通用式（1）的2,3-二氢苯并呋喃衍生物：其中R1代表氢原子或酰基；R2、R3和R4代表氢原子、较低的烷基或较低的烯基；R5和R6代表氢原子或可选择取代的烷基基团，或R5和R6结合形成环烷基或含有一个或多个氧原子或烷基取代的氮原子的饱和杂环基团，但R2和R3不能同时代表叔丁基基团，或其光学活性异构体或药学上可接受的盐可用作治疗或预防各种肾脏疾病和器官保护剂。

  公开号：

  US06403639B1
• 作为产物：
  描述：

  叔丁基对羟基茴香醚 在 硫酸 三甲基氯硅烷 、 sodium iodide 作用下， 以 水 、 溶剂黄146 、 乙腈 为溶剂， 生成 4-acetoxy-3-tert-butylphenol
  参考文献：
  名称：

  2,3-dihydrobenzofuran derivatives

  摘要：

  通用式（1）的2,3-二氢苯并呋喃衍生物：其中R1代表氢原子或酰基；R2、R3和R4代表氢原子、较低的烷基或较低的烯基；R5和R6代表氢原子或可选择取代的烷基基团，或R5和R6结合形成环烷基或含有一个或多个氧原子或烷基取代的氮原子的饱和杂环基团，但R2和R3不能同时代表叔丁基基团，或其光学活性异构体或药学上可接受的盐可用作治疗或预防各种肾脏疾病和器官保护剂。

  公开号：

  US06403639B1

文献信息

• 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030191181A1

  公开（公告）日：2003-10-09

  Compounds of Formula 1 1 wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  公式1的化合物 1 其中，变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，适用于治疗可用视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030207937A1

  公开（公告）日：2003-11-06

  Compounds of the formula 1 where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  具有公式1的化合物，其中变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并且适用于治疗可通过视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
  申请人：——

  公开号：US20040077721A1

  公开（公告）日：2004-04-22

  vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.

  维生素A，或具有维生素A活性的维生素A衍生物与CP450RAI1和/或CP450RAI2酶的抑制剂共同给药，用于治疗哺乳动物，包括人类的疾病和状况，这些疾病或状况可以通过施用视黄酸化合物或通过哺乳动物机体自然存在的视黄酸来预防、治疗、改善或延迟其发作。
• Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
  申请人：Allergan Sales, Inc.

  公开号：US06313107B1

  公开（公告）日：2001-11-06

  Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.

  具有1至8号式的新化合物，其中符号的含义在说明书中有定义，并且已发现某些先前已知的化合物可作为细胞色素P450RAI（诱导性维生素A酸）酶的抑制剂，并用于治疗对维生素A酸治疗产生响应的疾病。该化合物还可与维生素A酸一起进行联合治疗。
• Compounds having activity as inhibitors of cytochrome P450RAI
  申请人：Allergan Sales, Inc.

  公开号：US06252090B1

  公开（公告）日：2001-06-26

  Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

  具有化学式1的化合物，在该化学式中符号的含义如规范中定义的那样，是细胞色素P450RAI（视黄酸诱导）酶的抑制剂，并用于治疗对视黄醇类药物治疗有效的疾病。